drugset / Trial / NCT05661734
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Timeline
- Start
- 2023-01-09
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
Publications
- Yuan S, Ji H, Lu Y, Zhang Z, Tang H. The Clinical Application of Suzetrigine. J Pain Palliat Care Pharmacother. 2026 Jun;40(2):311-320. doi: 10.1080/15360288.2026.2624502. Epub 2026 Feb 14.
- McCoun J, Winkle P, Solanki D, Urban J, Bertoch T, Oswald J, Swisher MW, Taber LA, Healey T, Jazic I, Correll DJ, Negulescu PA, Bozic C, Weiner SG; VX-548-107 Study Team. Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. J Pain Res. 2025 Mar 25;18:1569-1576. doi: 10.2147/JPR.S509144. eCollection 2025.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suzetrigine | Small molecule | 50 mg | Oral |
Indications
No indication recorded.